Substituted 3-alkyl and 3-alkenyl azetidine derivatives

Details Substituted 3-alkyl and 3-alkenyl azetidine derivatives Substituted 3-alkyl and 3-alkenyl azetidine derivatives

2004-06-09

2009-02-03

Saeed, Kamal A (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07485732

ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

REFERENCES:
patent: 4052383 (1977-10-01), Gold et al.
patent: 4133881 (1979-01-01), Cale et al.
patent: 4242261 (1980-12-01), Cale
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6858603 (2005-02-01), Achard et al.
patent: 6872717 (2005-03-01), Achard et al.
patent: 2002/0016337 (2002-02-01), Cuny et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 1328269 (2004-05-01), None
patent: WO 97/46511 (1997-12-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 00/15609 (2000-03-01), None
patent: WO 00/71518 (2000-11-01), None
patent: WO 01/64632 (2001-09-01), None
patent: WO 01/64633 (2001-09-01), None
patent: WO 01/64634 (2001-09-01), None
patent: WO 01/64676 (2001-09-01), None
patent: WO 02/12187 (2002-02-01), None
patent: WO 03/007939 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 2004/056800 (2004-07-01), None
patent: WO 2004/096763 (2004-11-01), None
patent: WO 2004/096794 (2004-11-01), None
patent: WO 2005/000809 (2005-01-01), None
patent: WO 2005/077897 (2005-08-01), None
U.S. Appl. No. 11/602,577.
Lange et al., Drug Discovery Today, vol. 10 (2005), pp. 693-702, “Medicinal chemistry strategies to CB1 cannabinoind receptor antagonists”.
Adam et al., Exp. Opin. Ther. Patents, vol. 12 (2002), pp. 1475-1489, “Recent advances in the cannabinoids”.

Affiliated with

Also associated with

Rating

Substituted 3-alkyl and 3-alkenyl azetidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 3-alkyl and 3-alkenyl azetidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 3-alkyl and 3-alkenyl azetidine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4089171